by Julia Hanf
The research about stem cells has been very controversial. The issues in the advent of stem cell research as well as the health care distinction are some of the topics that have been delved into by many medical experts as well as those suffering from certain illnesses such as migraine and diabetes. The most part that has caught the interest of these experts is where these cells are from. There are so many sources associated with stem cells. These cells may either be from the blood in the umbilical cord, embryos or from old age.
The cure for diabetes, as well as more improved treatments, may lie in stem cell research. The American Diabetes Association supports this type of research, and has worked diligently to obtain funding. The American Diabetes Association is also fighting to eliminate bans on stem cell research pertaining to diabetes.
Moreover, there are also some universities such as Stanford University and UC Berkeley that voiced out their support on this research by motivating scientists who are involve in the research.
Doctors, biologists, chemists, engineers and computer scientists from the two schools formerly cited, are joining forces to talk about their effort and to contributions with students and staff.
Both universities are deeply caught up in embryonic stem cell research, which scientists anticipate will provide treatments or cures for such diseases as diabetes, Alzheimer’s and Parkinson’s.
As a representation of their new collaboration, the campuses intend to set aside space in their stem cell laboratories for visiting researchers who choose to spend their sabbaticals working with peers at the other school.
A biotechnology company, VistaGen Therapeutics, Inc., make use of embryonic stem cell technologies to discover and create new drugs for diabetes, publicized an extensive embryonic stem cell research unification with Toronto’s University Health Network, Canada’s foremost research hospital, and its stem cell research associate, the McEwen Centre for Regenerative Medicine.
The new alliance positions Vista-Gen to continue to influence the embryonic stem cell biology knowledge and leading-edge embryonic stem cell technologies of Dr. Gordon Keller, one of the world’s leading stem cell researchers and the Director of the McEwen Centre for Regenerative Medicine. VistaGen and Dr. Keller anticipate conducting research into advanced techniques to tell the difference between embryonic stem cells into mature cardiac, liver, and pancreatic beta-islet cells. This will improve VistaGen’s industry-leading, in vitro biological systems and bio informatics databases for prognostic toxicology applications.
The new supported research program is put together on VistaGen’s present strategic licenses to Dr. Keller’s past embryonic stem cell intellectual property, and envelops new embryonic stem cell-based research projects.
VistaGen is also hopeful that the outcomes of the stem cell research will be useful in developing and finding the newer invention for the different systems that would be used in embryonic stem cell-based liver, pancreas and cardiac beta-islet differentiation. Moreover, VistaGen is hopeful that the results will be used to develop pioneering medications for heart and liver diseases as well as diabetes.
Yet another group of researchers from the Spring Point Project has been leading efforts to provide a cure by injecting insulin-producing islet cells from pigs into diabetics. Research showed that transplanting healthy human islet cells in diabetics could turn around the disease. But due to a shortage of human donor organs access is limited to such cells.
Dr. Bernhard Hering, a world-renowned diabetes expert and scientific director of the Diabetes Institute for Immunology and Transplantation at the University of Minnesota, and his panel experimented with pig islet cell transplants on monkeys and discovered that those cell transplants resulted in long-term diabetes reversal in the monkeys. A PowerPoint presentation included a chart that depicted erratic blood sugar counts in the monkeys getting to a level point. The use of pig parts in humans has been doing well in other areas, including pig valves or bowels in transplants. Pig skin is also used in burn centers to substitute human skin.
The fact that the foreign cells are introduced to the body, the receiver of the transplant needs medication intake to ensure that the cells will not be rejected. Side effects are expected however, the severity of these signs and symptoms are yet to be discovered. It is also said that these effects may change and depend according to what type of patients they have.
Perhaps in the imminent future, may be as close as 2009, the first experimental trials will be planned for individuals with the severest type of diabetes who are incapable of controlling their blood sugar levels and may suffer unexpected blackouts or other episodes.
The controversy on the research about stem cells are yet to end until the status will be different from the present. The issues and controversies may only end if the stem cells will be developed from a specific source.
By Guest Author:
Julia Hanf author of the book How To Play the Diabetes Diet Game and Win Through a real life crisis Julia figured out how to live diabetes free. Visit
http://www.yourdiabetescure.com and learn more about your solution for diabetes.